Financial Data and Key Metrics Changes - Total net revenue for the company's prescription products was approximately $2.2 million in Q1 2025, a decrease of approximately 6% compared to $2.4 million in Q1 2024 and a 37% decrease from $3.5 million in Q4 2024 [27] - Loss from operations increased by $1.2 million from $8.2 million in Q1 2024 to $9.4 million in Q1 2025 [28] - Net loss attributable to common shareholders increased by approximately $1.2 million from $9.2 million in Q1 2024 to $10.4 million in Q1 2025 [28] Business Line Data and Key Metrics Changes - Mytesi prescription volume increased by approximately 1.8% in Q1 2025 compared to Q1 2024 but decreased by approximately 13.5% compared to Q4 2024 [27] - Dispensed prescriptions for Mytesi and Profelymer increased by approximately 2% in Q1 2025 compared to Q1 2024, indicating increased demand [5] Market Data and Key Metrics Changes - Short bowel syndrome affects approximately 10,000 to 20,000 people in Europe and a similar number in the United States, qualifying for orphan designation [19] - MVID is an ultra-rare condition with an estimated prevalence of just a couple hundred patients globally [19] Company Strategy and Development Direction - The company is focusing on the convergence of key catalysts that are expected to enhance value for stakeholders, including paradigm-shifting medicines and mechanisms of action [6] - There are ongoing proof of concept trials for crofelemer in both pediatric and adult patients with rare diseases, which are expected to yield results throughout 2025 and into 2026 [21] - The company is also exploring business development opportunities related to its product CANALIVIA CA1 for chemotherapy-induced diarrhea in dogs, aiming to expand its approval [31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the multiple expected near-term catalysts throughout 2025 and early 2026, viewing them as potentially transformative for stakeholders [30] - The company is committed to enhancing collaborations and licensing deals to support late-stage products and programs [30] Other Important Information - The initial proof of concept results for crofelemer showed a reduction in TPN by up to 27% for MVID patients and 12.5% for pediatric SBS patients, which could modify disease progression [12] - The FDA has granted a Type C meeting to discuss the responder analysis for breast cancer patients in the on-target study, indicating a pathway for making profelymer available for cancer therapy-related diarrhea [23] Q&A Session Summary Question: What are the expected catalysts for the company in the near term? - Management highlighted multiple expected catalysts throughout 2025 and early 2026 that are viewed as important for enhancing value for stakeholders [30] Question: How does the company plan to address the unmet needs in the supportive care area for cancer treatment? - The company is focusing on addressing the supportive care needs for cancer treatment, particularly related to diarrhea, which can impact treatment outcomes [25]